Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review

BACKGROUND AND OBJECTIVE: While anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard of care treatment for metastatic ALK-positive non-small cell lung cancer (NSCLC), the benefit of moving ALK inhibitors to earlier disease stages is unclear. The objective of this review is...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Monica F., Chaft, Jamie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989809/
https://www.ncbi.nlm.nih.gov/pubmed/36895922
http://dx.doi.org/10.21037/tlcr-22-631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989809/
https://www.ncbi.nlm.nih.gov/pubmed/36895922
http://dx.doi.org/10.21037/tlcr-22-631

Ejemplares similares